{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:15:31Z","timestamp":1765728931617,"version":"build-2065373602"},"reference-count":43,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Highly effective modulator therapy (HEMT) has been available for adults and young adults aged 12 years and over with cystic fibrosis for approximately 5 years, with real-world evidence (RWE) emerging that confirms the significant impacts of these novel medications in older patient groups. As licensing has been extended to younger children (2 years and above in some jurisdictions), we summarize the clinical experience of these medications in pre-school and school-aged children and compare how changes in the objective markers of the disease can be elucidated in younger children. We also discuss the different incidences and severity of side effect profiles, the efforts to mediate these in younger children, and the particular challenges in introducing novel medications into pediatrics. We speculate on the use of HEMT in younger infants and its potential use in prenatal care.<\/jats:p>","DOI":"10.3390\/jcm14134625","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T13:06:17Z","timestamp":1751288777000},"page":"4625","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impacts and New Challenges with Highly Effective Modulator Therapies in Younger Children with Cystic Fibrosis"],"prefix":"10.3390","volume":"14","author":[{"given":"Kanchana","family":"Uyangoda","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine and Cystic Fibrosis, Great Ormond Street Hospital, London WC1N 3JH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5209-3286","authenticated-orcid":false,"given":"Charlotte","family":"Dawson","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Cystic Fibrosis, Great Ormond Street Hospital, London WC1N 3JH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikesh","family":"Gudka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Cystic Fibrosis, Great Ormond Street Hospital, London WC1N 3JH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossa","family":"Brugha","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Cystic Fibrosis, Great Ormond Street Hospital, London WC1N 3JH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: A global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"113195","DOI":"10.1016\/j.ejmech.2021.113195","article-title":"Modulators of CFTR. Updates on clinical development and future directions","volume":"213","author":"Bardin","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-med-042921-021447","article-title":"Cystic Fibrosis Modulator Therapies","volume":"74","author":"Jia","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.biocel.2014.02.023","article-title":"Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies","volume":"52","author":"Fanen","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"eS8","DOI":"10.1016\/S0929-693X(20)30044-0","article-title":"CFTR gene variants, epidemiology and molecular pathology","volume":"27","author":"Bareil","year":"2020","journal-title":"Arch. Pediatr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with aG551DMutation","volume":"187","author":"Davies","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1378\/chest.11-2672","article-title":"Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation","volume":"142","author":"Flume","year":"2012","journal-title":"Chest"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharma-codynamics of ivacaftor in patients aged 2\u20135 years with cystic fibrosis and a CFTR gating mutation (KIWI): An open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S2213-2600(20)30510-5","article-title":"Long-term safety and efficacy of tezacaftor\u2013ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): An open-label extension study","volume":"9","author":"Flume","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2401146","DOI":"10.1183\/13993003.01146-2024","article-title":"Impact of the expanded label for elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with no F508del variant in the USA","volume":"64","author":"Cromwell","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"The expanded French compassionate programme for elexacaftor\u2013tezacaftor\u2013ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: A real-world study","volume":"12","author":"Burgel","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S2213-2600(24)00407-7","article-title":"Vanzacaftor-tezacaftor-deutivacaftor for children aged 6\u201311 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): An analysis from a single-arm, phase 3 trial","volume":"13","author":"Hoppe","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical Effectiveness of Elexa-caftor\/Tezacaftor\/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100690","DOI":"10.1016\/j.lanepe.2023.100690","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: Real-world evidence from the German CF Registry","volume":"32","author":"Sutharsan","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and Safety of Elexa-caftor\/Tezacaftor\/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study","volume":"206","author":"Mall","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2000006","DOI":"10.1183\/13993003.00006-2020","article-title":"An observational study of the lung clearance index throughout childhood in cystic fibrosis: Early years matter","volume":"56","author":"Davies","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A Phase 3 Open-Label Study of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1164\/rccm.202301-0021OC","article-title":"Long-Term Safety and Efficacy of Elexa-caftor\/Tezacaftor\/Ivacaftor in Children Aged \u22656 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial","volume":"208","author":"Wainwright","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Olivier, M., Kavvalou, A., Welsner, M., Hirtz, R., Stra\u00dfburg, S., Sutharsan, S., Stehling, F., and Steindor, M. (2023). Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1176815"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 Open-Label Clinical Trial of Elexacaftor\/Tezacaftor\/Ivacaftor in Children Aged 2\u20135 Years with Cystic Fibrosis and at Least One F508del Allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1002\/ppul.27272","article-title":"Effects on growth, weight and body composition after CFTR modulators in children with cystic fibrosis","volume":"59","author":"Castro","year":"2024","journal-title":"Pediatr. Pulmonol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jcf.2023.08.002","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis","volume":"22","author":"Hergenroeder","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jcf.2023.04.019","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on fat-soluble vitamin levels in children with cystic fibrosis","volume":"22","author":"Schembri","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40348-024-00178-6","article-title":"Changes in vitamins and trace elements after initiation of highly effective CFTR modulator therapy in children and adults with cystic fibrosis\u2014A real-life insight","volume":"11","author":"Fabricius","year":"2024","journal-title":"Mol. Cell. Pediatr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): A phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1002\/ppul.24952","article-title":"Sustained recovery of exocrine pancreatic function in a teenager with cystic fibrosis treated with ivacaftor","volume":"55","author":"Smith","year":"2020","journal-title":"Pediatr. Pulmonol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jcf.2023.08.009","article-title":"Chronic rhinosinusitis in the era of CFTR modulator therapy","volume":"23","author":"Stone","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/apm.13427","article-title":"The criteria for chronic rhinosinusitis in children with cystic fibrosis are rarely fulfilled after initiation of CFTR modulator treatment","volume":"132","author":"Bech","year":"2024","journal-title":"APMIS"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1007\/s00405-023-07859-4","article-title":"Effects of CFTR-modulator triple therapy on sinunasal symptoms in children and adults with cystic fibrosis","volume":"280","author":"Bode","year":"2023","journal-title":"Eur. Arch. Oto-Rhino-Laryngol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): Results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jcf.2024.03.012","article-title":"Safety and efficacy of ivacaftor in infants aged 1 to less than 4 months with cystic fibrosis","volume":"23","author":"McNally","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jcf.2019.03.009","article-title":"An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2\u20135 years (KLIMB)","volume":"18","author":"Rosenfeld","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e71067","DOI":"10.1002\/ppul.71067","article-title":"Real World Adverse Effects of Elexacaftor\/Tezacaftor\/Ivacaftor in People With Cystic Fibrosis Ages 6\u201311 Years","volume":"60","author":"Pettit","year":"2025","journal-title":"Pediatr. Pulmonol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(24)01134-6","article-title":"on behalf of the MODUL-CF study group. Behavioural and sleep issues after initiation of elexacaftor\u2013tezacaftor\u2013ivacaftor in preschool-age children with cystic fibrosis","volume":"404","author":"Benaboude","year":"2024","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"114176","DOI":"10.1016\/j.jpeds.2024.114176","article-title":"Reported Adverse Events in a Multicenter Cohort of Patients Ages 6\u201318 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"274","author":"Terlizzi","year":"2024","journal-title":"J. Pediatr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jcf.2025.03.009","article-title":"First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF study","volume":"24","author":"Bonnel","year":"2025","journal-title":"J. Cyst. Fibros."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/13\/4625\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:01:47Z","timestamp":1760032907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/13\/4625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":43,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["jcm14134625"],"URL":"https:\/\/doi.org\/10.3390\/jcm14134625","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}